Aller au contenu principal
Accès ouvert déclaré 2026 article

A UK-wide analysis of the use of reversal agents in 198 patients on direct oral anticoagulants prior to urgent procedures

0Citations signalées — pas une note de qualité
0Institutions déclarées
0Pays d’affiliation déclarés

Résumé fourni par la source

Background: Direct oral anticoagulants (DOACs) are widely prescribed but present challenges when patients require urgent invasive procedures. While idarucizumab is licensed for preprocedural reversal of dabigatran, 4-factor prothrombin complex concentrates (4F-PCCs) are often used off-label for oral factor (F)Xa inhibitors. Objectives: We aimed to describe real-world UK use of reversal agents prior to urgent procedures. Methods: We conducted a UK-wide audit of adults receiving andexanet alfa, idarucizumab, or 4F-PCC to reverse apixaban, dabigatran, edoxaban, or rivaroxaban, before urgent procedures between October 2020 and June 2023. Data were collected by members of HaemSTAR, a UK-wide network led by hematology resident doctors. Primary outcomes were (1) receipt of reversal ≤24 hours before procedure and (2) adherence to recommended dosing. Secondary outcomes included procedural bleeding risk, 90-day mortality, and 30-day thrombosis rate. Results: Data were collected on 198 patients, with 48% undergoing high-risk procedures. Median time from reversal to procedure was 1.6 hours and 76% took place within 24 hours. 4F-PCC was used in 87%, idarucizumab in 8%, and andexanet alfa in 5%. Tranexamic acid was administered in 20%, 90-day mortality was 24%, and thromboembolic events occurred in 3%, all following 4F-PCC. Conclusion: Reversal agents are frequently used prior to urgent procedures in direct oral anticoagulant-treated patients, including for low-risk interventions. There is limited evidence to support the off-label use of 4F-PCC; the risks, benefits, and cost effectiveness are uncertain. Delays to intervention, low use of tranexamic acid, and infrequent drug-level testing highlight opportunities to improve clinical workflows and inform future trials.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
A UK-wide analysis of the use of reversal agents in 198 patients on direct oral anticoagulants prior to urgent procedures
Date Crossref
01/05/2026
Éditeur
Elsevier BV
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude et ne compte pas comme une seconde source scientifique indépendante.

Sujets associés

Atrial Fibrillation Management and OutcomesCardiac, Anesthesia and Surgical OutcomesVenous Thromboembolism Diagnosis and Management

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.